A Memorial Sloan Kettering Cancer Center study reveals new details about how pancreatic cells carrying oncogenic mutations ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, ...
PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended ...
Zacks Investment Research on MSN
10x Genomics stock up on Atera launch, spatial biology scale enhanced
10x Genomics TXG recently unveiled Atera, a next-generation in situ spatial biology platform designed to deliver ...
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc.
Flagship challenge will award an in situ multiomic study on G4X up to 1,000 samples, opening the door to larger cohort-based spatial research in oncology and translational science SAN DIEGO, March 26, ...
The ventral tegmental area (VTA) is a key site for opioid actions, and emerging evidence suggests that pain states and opioid experience both induce transcriptional, molecular, and circuit adaptations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results